Combined therapy with Endoret‐Gel and plasma rich in growth factors vs Endoret‐Gel alone in the management of facial rejuvenation: A comparative study

Abstract

Background Skin suffers progressive decrement. An endogenous regenerative technology has been developed that has the versatility to provide an autologous injectable gel (Endoret‐Gel) or a liquid plasma rich in growth factors (PRGF) based on the patient´s own platelet‐rich plasma. Aims To compare the efficacy of the combined therapy with Endoret‐Gel and PRGF versus Endoret‐Gel alone in the management of facial rejuvenation. Methods Twenty clinically diagnosed patients with aged skin received either Endoret‐Gel monotherapy or Endoret‐Gel + PRGF combined therapy. Patients underwent three sessions at one‐month intervals and were clinically assessed for six months. Corneometry, sebumetry, and high‐resolution topographic analysis were carried out. Patient self‐assessment questionnaires and clinical improvement scores were also performed. Results The combined therapy showed to promote a higher hydration index. These results were also significant for spot improvement at three months, while conversely, monotherapy with Endoret‐Gel demonstrated higher UV spot improvement. A significant decrease of sebum production and wrinkle development was observed for both treatment groups. Red areas also improved in a similar way at the end of the follow‐up period. After Endoret‐Gel or Endoret‐Gel + PRGF therapy, 30% and 70% of patients referred to be very satisfied, respectively. Accordingly, 40% and 80% showed a “very improved” esthetic performance. None of the patients reported a negative change and no adverse events were recorded. Conclusion Both Endoret‐Gel monotherapy and the combined treatment with PRGF were shown to promote facial rejuvenation and to palliate the age‐related cutaneous atrophy. The combined therapy may exert a synergistic effect that addresses both skin quality improvement and soft tissue restoration in a shorter period.

Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases

“…Furthermore, one of the main characteristics of PRGF technology is its versatility since several formulations can be obtained from the same initial product [ 6 ]. After activation with calcium chloride, an injectable formulation can be obtained which has been used for the treatment of various pathologies in different medical fields such as dentistry, dermatology, and traumatology [ 7 , 8 ]. Moreover, if PRGF is incubated for 40 to 60 min at 37 °C after platelet activation, a supernatant rich in growth factors is obtained [ 9 ].…”